CSIMarket
 


Nautilus Biotechnology Inc   (NAUT)
Other Ticker:  
 
 

NAUT's Capital Expenditures Growth by Quarter and Year

Nautilus Biotechnology Inc 's Capital Expenditures results by quarter and year




NAUT Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 0.41 0.23 0.99 0.00
III Quarter September 0.87 0.96 0.27 0.00
II Quarter June 0.46 0.65 1.01 0.00
I Quarter March 0.69 0.48 0.00 0.00
FY   2.43 2.32 2.27 0.00



NAUT Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Nautilus Biotechnology Inc achieved in the fourth quarter 2023, above Company average Capital Expenditures rise of 79.57% year on year, to $ 0.41 millions.

Looking into fourth quarter 2023 results within Laboratory Analytical Instruments industry 3 other companies have achieved higher Capital Expenditures growth. While Nautilus Biotechnology Inc ' s Capital Expenditures jump of 79.57% ranks overall at the positon no. 1069 in the fourth quarter 2023.




NAUT Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 79.57 % -76.77 % - -
III Quarter September -9.38 % 255.56 % - -
II Quarter June -29.23 % -35.64 % - -
I Quarter March 43.75 % - - -
FY   4.87 % 2.2 % - -

Financial Statements
Nautilus Biotechnology Inc 's fourth quarter 2023 Capital Expenditures $ 0.41 millions NAUT's Income Statement
Nautilus Biotechnology Inc 's fourth quarter 2022 Capital Expenditures $ 0.23 millions Quarterly NAUT's Income Statement
New: More NAUT's historic Capital Expenditures Growth >>


NAUT Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -52.53 % -76.04 % 266.67 % -
III Quarter September 89.13 % 47.69 % -73.27 % -
II Quarter June -33.33 % 35.42 % - -
I Quarter March 200 % -51.52 % - -
FY (Year on Year)   4.87 % 2.2 % - -




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #4
Healthcare Sector #127
Overall #1069

Capital Expenditures Y/Y Growth Statistics
High Average Low
5.08 % -7.79 % -26.71 %
(Dec 31 2023)   (Sep 30 2023)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #4
Healthcare Sector #127
Overall #1069
Capital Expenditures Y/Y Growth Statistics
High Average Low
5.08 % -7.79 % -26.71 %
(Dec 31 2023)   (Sep 30 2023)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Nautilus Biotechnology Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
265.19 % 35.28 % -76.22 %
(Dec 31 2021)  


NAUT's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Nautilus Biotechnology Inc disclosed fall in Capital Expenditures from the third quarter by -52.53% to $ 0.41 millions, from $ 0.87 millions released in the previous reporting period.

As we look into recent shortcoming in the quarter, we suppose to assume, that commonly IV. Quarter Capital Expenditures occur weaker in contrast to the quarter before, Elijah  B. Johnson, an industry advisor said.

Within Laboratory Analytical Instruments industry 5 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Nautilus Biotechnology Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1516.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #6
Healthcare Sector #196
Overall #1516
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #6
Healthcare Sector #196
Overall #1516
Capital Expenditures Q/Q Growth Statistics
High Average Low
265.19 % 35.28 % -76.22 %
(Dec 31 2021)  


NAUT's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Nautilus Biotechnology Inc reported fall in Capital Expenditures from the third quarter by -52.53% to $ 0.41 millions, from $ 0.87 millions declared in the previous quarter.

As we analyse present shortcoming in the quarter, we must assume, that usually IV. Quarter 2023 results occur softer then in the preciding period, Elijah  B. Johnson, an industry advisor added.

Within Laboratory Analytical Instruments industry 5 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Nautilus Biotechnology Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1516.


Nautilus Biotechnology Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 2.44 $ 2.26 $ 2.35 $ 2.54 $ 2.32
Y / Y Capital Expenditures Growth (TTM) 5.08 % -26.71 % -1.72 % -7.82 % -
Year on Year Capital Expenditures Growth Overall Ranking # 879 # 1584 # 435 # 0 # 0
Seqeuential Capital Expenditures Change (TTM) 8.15 % -3.79 % -7.42 % 9.08 % -24.57 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1069 # 804 # 11 # 433 # 1864




Cumulative Capital Expenditures growth Comment
With 5.08% annual Capital Expenditures growth, Nautilus Biotechnology Inc would report a record annual Capital Expenditures improvement if the fiscal year would end on Dec 31 2023.

In the Healthcare sector 106 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 879, from total ranking in previous quarter at 1584.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
5.08 %
-7.79 %
-26.71 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 4
Healthcare Sector # 107
Overall # 879

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
5.08 %
-7.79 %
-26.71 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 127
S&P 500 # 1069
Cumulative Capital Expenditures growth Comment
With 5.08% annual Capital Expenditures growth, Nautilus Biotechnology Inc would report a record annual Capital Expenditures improvement if the fiscal year would end on Dec 31 2023.

In the Healthcare sector 106 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 879, from total ranking in previous quarter at 1584.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
5.08 %
-7.79 %
-26.71 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 4
Healthcare Sector # 107
Overall # 879

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
5.08 %
-7.79 %
-26.71 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 127
S&P 500 # 1069




Other Capital Expenditures Growth
Laboratory Analytical Instruments Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
NAUT's Capital Expenditures Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for NAUT's Competitors
Capital Expenditures Growth for Nautilus Biotechnology Inc 's Suppliers
Capital Expenditures Growth for NAUT's Customers

You may also want to know
NAUT's Annual Growth Rates NAUT's Profitability Ratios NAUT's Asset Turnover Ratio NAUT's Dividend Growth
NAUT's Roe NAUT's Valuation Ratios NAUT's Financial Strength Ratios NAUT's Dividend Payout Ratio
NAUT's Roa NAUT's Inventory Turnover Ratio NAUT's Growth Rates NAUT's Dividend Comparisons



Companies with similar Capital Expenditures improvement for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Moderna Inc 139.13%$ 139.130 millions
Cellectar Biosciences inc 126.34%$ 126.341 millions
Inspiremd Inc 126.32%$ 126.316 millions
Cvrx inc113.92%$ 113.924 millions
Eli Lilly And Company113.82%$ 113.821 millions
Alpha Pro Tech Ltd 113.29%$ 113.287 millions
Docgo Inc 112.42%$ 112.423 millions
Castle Biosciences Inc 112.26%$ 112.255 millions
Beyond Air Inc 110.88%$ 110.883 millions
Editas Medicine Inc 109.46%$ 109.455 millions
Agios Pharmaceuticals Inc 107.08%$ 107.080 millions
United Therapeutics Corporation99.24%$ 99.241 millions
Zymeworks Inc 98.64%$ 98.641 millions
Proqr Therapeutics N v 93.64%$ 93.644 millions
National Research Corporation91.76%$ 91.760 millions
Kiromic Biopharma Inc 90.73%$ 90.734 millions
Irhythm Technologies Inc 90.57%$ 90.568 millions
Tandem Diabetes Care Inc 88.36%$ 88.360 millions
Agilon Health Inc 85.12%$ 85.125 millions
Schrodinger Inc 84.18%$ 84.175 millions
Dynatronics Corporation83.55%$ 83.547 millions
Nautilus Biotechnology Inc 80.35%$ 80.349 millions
Elanco Animal Health Inc77.22%$ 77.215 millions
Arrowhead Pharmaceuticals Inc 76.44%$ 76.444 millions
Renovaro Inc 75.96%$ 75.957 millions
Neuronetics inc 74.75%$ 74.751 millions
Integra Lifesciences Holdings Corp69.72%$ 69.722 millions
Bausch and Lomb Corp68.00%$ 68.000 millions
Entera Bio Ltd 66.67%$ 66.667 millions
Perrigo Company Plc65.84%$ 65.839 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com